VAChT特异性PET放射性配体18F-VAT在人体内的辐射剂量学及空腹依赖性肝胆清除
本研究在8名健康受试者中评估18F-VAT的全身生物分布与辐射剂量学,受试者分别处于完全空腹、部分空腹或非空腹状态。胆囊为关键器官(201.0 μSv/MBq),性别平均有效剂量为17.5 ± 2.1 μSv/MBq。结论指出,在不考虑空腹状态时,可给予最多249 MBq而不超过胆囊50 mSv的剂量限值;口服补充剂可加速胆囊清除,使部分空腹状态下可给予465 MBq。
要点
- 胆囊为18F-VAT的关键器官(201.0 μSv/MBq),其次为肝脏(64.3 μSv/MBq)。
- 性别平均有效剂量为17.5 ± 2.1 μSv/MBq,男性15.7、女性19.4 μSv/MBq。
- 不考虑空腹状态时,最多可给予249 MBq而不超过胆囊50 mSv限值。
核心结论
- 人体生物分布数据显示18F-VAT在胆囊和肝脏中滞留较高,大鼠剂量学研究因缺乏胆囊而不能准确预测安全性。
- 人体剂量学数据与非人灵长类空腹数据不同,表明不考虑空腹状态时最多可给予249 MBq(6.7 mCi)的18F-VAT而不超过胆囊50 mSv(5 rem)的最大剂量。
- 在给药前及尤其是给药后90分钟口服补充剂可加速胆囊清除,降低关键器官辐射暴露,使部分空腹状态下可给予465 MBq(12.6 mCi)而不超过胆囊50 mSv(5 rem)。
研究设计与样本
- 基于临床前数据,8名健康受试者(4男4女)接受385-533 MBq 18F-VAT后立即进行三次连续全身PET/CT扫描。
- PET数据在三种不同空腹条件下采集:完全空腹(n=3)、口服部分空腹(n=3)或非空腹(n=2),相对于给予Ensure®Plus口服补充剂和PET图像采集的时间。
- 定义感兴趣体积(VOIs)并生成器官时间-放射性曲线(TACs),使用OLINDA/EXM v2.2软件计算器官辐射剂量学。
主要发现
- 18F-VAT给药后无不良事件。
- 放射性主要累积于脑、肝胆系统、小肠、骨和膀胱。
- 在所有空腹状态下,器官剂量学显示胆囊为关键器官(201.0 μSv/MBq),其次为肝脏(64.3 μSv/MBq),性别平均有效剂量为17.5 ± 2.1 μSv/MBq(男性15.7、女性19.4 μSv/MBq)。
- 平均胆囊时间积分活度在非空腹(36.6 MBq*h,155.5 µSv/MBq)、部分空腹(21.8 MBq*h,107.6 µSv/MBq)和空腹PET采集(74.1 MBq*h,270.5 µSv/MBq)间显著不同(Kruskal-Wallis H 6.5,p = 0.04)。
关键数值与推荐
- 胆囊关键器官剂量为201.0 μSv/MBq,肝脏为64.3 μSv/MBq。
- 性别平均有效剂量为17.5 ± 2.1 μSv/MBq(男性15.7 μSv/MBq,女性19.4 μSv/MBq)。
- 非空腹组胆囊时间积分活度为36.6 MBq*h(155.5 µSv/MBq),部分空腹组为21.8 MBq*h(107.6 µSv/MBq),空腹PET采集组为74.1 MBq*h(270.5 µSv/MBq),组间差异Kruskal-Wallis H 6.5,p = 0.04。
- 不考虑空腹状态时,可给予最多249 MBq(6.7 mCi)而不超过胆囊50 mSv(5 rem)。
- 在最佳部分空腹状态下,可给予465 MBq(12.6 mCi)而不超过胆囊50 mSv(5 rem)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The vesicular acetylcholine transporter ligand (-)-(1-((2R,3R)-8-(2-[(18)F]fluoro-ethoxy)-3-hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)piperidin-4-yl)(4-fluorophenyl)-methanone (18F -VAT) enables positron emission tomography PET quantification of cholinergic dysfunction in neurologic and psychiatric disorders. Determining its bio-distribution and dose exposure in humans is essential for clinical implementation, particularly given hepatobiliary clearance observed in pre-clinical models. Based on pre-clinical data, eight healthy subjects (4 males, 4 females) received 385-533 MBq 18F-VAT immediately followed by three sequential whole-body PET/CT scans. PET data were collected under three different fasting conditions relative to administration of Ensure®Plus oral supplement and PET image acquisition: (1) complete fasting (n = 3), (2) oral partial fasting (n = 3), or (3) non-fasting (n = 2). We defined volumes of interest (VOIs), and generated organ time-activity curves (TACs). Organ radiation dosimetry was calculated using OLINDA/EXM v2.2 software. RESULTS: There were no adverse events after 18F-VAT dosing. Radioactivity accumulated predominantly in the brain, hepatobiliary system, small intestine, bone, and urinary bladder. Across all fasting states, organ dosimetry revealed gallbladder as the critical organ (201.0 μSv/MBq) followed by liver (64.3 μSv/MBq), with a gender averaged effective dose of 17.5 ± 2.1 μSv/MBq (15.7 and 19.4 μSv/MBq for males and females, respectively.) Mean gallbladder time integrated activity significantly differed across non-fasting (36.6 MBq*h, 155.5 µSv/MBq), partial fasting (21.8 MBq*h, 107.6 µSv/MBq) and fasting PET acquisition (74.1 MBq*h, 270.5 µSv/MBq) (Kruskal-Wallis H 6.5, p = 0.04). CONCLUSIONS: Human bio-distribution data showed high retention of 18F-VAT in the gallbladder and liver, where rat dosimetry studies do not accurately predict a safety profile given lack of gallbladder. Human dosimetry data appear different from fasting non-human primate data, indicating that up to 249 MBq (6.7 mCi) of 18F-VAT can be administered without exceeding a maximum dose to the gallbladder of 50 mSv (5 rem) without consideration of fasting state. Oral supplementation, administered just before and especially 90 min after 18F-VAT administration, accelerates gallbladder clearance. This reduces critical organ radiation exposure, allowing an administered dose of 18F-VAT to 465 MBq (12.6 mCi) in the optimal partial fasting state without exceeding a gallbladder dose of 50 mSv (5 rem).
引用
- Norris SA, Goldman NL, Hamdi M, et al. Radiation dosimetry and fasting-dependent hepatobiliary clearance of the VAChT-specific PET radioligand 18F-VAT in humans. EJNMMI Res. 2025. PMID: 40622650. doi:10.1186/s13550-025-01273-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。